Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates

Shannan Rossi, Jason E. Comer, Eryu Wang, Sasha R. Azar, William Lawrence, Jessica Plante, Katrin Ramsauer, Sabrina Schrauf, Scott Weaver

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND: Chikungunya virus (CHIKV) infection can result in chikungunya fever (CHIKF), a self-limited acute febrile illness that can progress to chronic arthralgic sequelae in a large percentage of patients. A new measles virus-vectored vaccine was developed to prevent CHIKF, and we tested it for immunogenicity and efficacy in a nonhuman primate model. METHODS: Nine cynomolgus macaques were immunized and boosted with the measles virus-vectored chikungunya vaccine or sham-vaccinated. Sera were taken at multiple times during the vaccination phase to assess antibody responses against CHIKV. Macaques were challenged with a dose of CHIKV previously shown to cause fever and viremia, and core body temperature, viremia, and blood cell and chemistry panels were monitored. RESULTS: The vaccine was well tolerated in all macaques, and all seroconverted (high neutralizing antibody [PRNT80 titers, 40-640] and enzyme-linked immunosorbent assay titers) after the boost. Furthermore, the vaccinated primates were protected against viremia, fever, elevated white blood cell counts, and CHIKF-associated cytokine changes after challenge with the virulent La Reunión CHIKV strain. CONCLUSIONS: These results further document the immunogenicity and efficacy of a measles-vectored chikungunya vaccine that shows promise in Phase I-II clinical trials. These findings are critical to human health because no vaccine to combat CHIKF is yet licensed.

Original languageEnglish (US)
Pages (from-to)735-742
Number of pages8
JournalThe Journal of infectious diseases
Volume220
Issue number5
DOIs
StatePublished - Jul 31 2019

Fingerprint

Measles virus
Primates
Chikungunya virus
Vaccines
Viremia
Macaca
Fever
Phase II Clinical Trials
Clinical Trials, Phase I
Measles
Neutralizing Antibodies
Body Temperature
Leukocyte Count
Antibody Formation
Blood Cells
Vaccination
Enzyme-Linked Immunosorbent Assay
Chikungunya Fever
Cytokines
Health

Keywords

  • chikungunya virus
  • measles virus
  • nonhuman primate
  • vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates. / Rossi, Shannan; Comer, Jason E.; Wang, Eryu; Azar, Sasha R.; Lawrence, William; Plante, Jessica; Ramsauer, Katrin; Schrauf, Sabrina; Weaver, Scott.

In: The Journal of infectious diseases, Vol. 220, No. 5, 31.07.2019, p. 735-742.

Research output: Contribution to journalArticle

Rossi, Shannan ; Comer, Jason E. ; Wang, Eryu ; Azar, Sasha R. ; Lawrence, William ; Plante, Jessica ; Ramsauer, Katrin ; Schrauf, Sabrina ; Weaver, Scott. / Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates. In: The Journal of infectious diseases. 2019 ; Vol. 220, No. 5. pp. 735-742.
@article{06657bd4b8a0418c810d95c832b000d9,
title = "Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates",
abstract = "BACKGROUND: Chikungunya virus (CHIKV) infection can result in chikungunya fever (CHIKF), a self-limited acute febrile illness that can progress to chronic arthralgic sequelae in a large percentage of patients. A new measles virus-vectored vaccine was developed to prevent CHIKF, and we tested it for immunogenicity and efficacy in a nonhuman primate model. METHODS: Nine cynomolgus macaques were immunized and boosted with the measles virus-vectored chikungunya vaccine or sham-vaccinated. Sera were taken at multiple times during the vaccination phase to assess antibody responses against CHIKV. Macaques were challenged with a dose of CHIKV previously shown to cause fever and viremia, and core body temperature, viremia, and blood cell and chemistry panels were monitored. RESULTS: The vaccine was well tolerated in all macaques, and all seroconverted (high neutralizing antibody [PRNT80 titers, 40-640] and enzyme-linked immunosorbent assay titers) after the boost. Furthermore, the vaccinated primates were protected against viremia, fever, elevated white blood cell counts, and CHIKF-associated cytokine changes after challenge with the virulent La Reuni{\'o}n CHIKV strain. CONCLUSIONS: These results further document the immunogenicity and efficacy of a measles-vectored chikungunya vaccine that shows promise in Phase I-II clinical trials. These findings are critical to human health because no vaccine to combat CHIKF is yet licensed.",
keywords = "chikungunya virus, measles virus, nonhuman primate, vaccine",
author = "Shannan Rossi and Comer, {Jason E.} and Eryu Wang and Azar, {Sasha R.} and William Lawrence and Jessica Plante and Katrin Ramsauer and Sabrina Schrauf and Scott Weaver",
year = "2019",
month = "7",
day = "31",
doi = "10.1093/infdis/jiz202",
language = "English (US)",
volume = "220",
pages = "735--742",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates

AU - Rossi, Shannan

AU - Comer, Jason E.

AU - Wang, Eryu

AU - Azar, Sasha R.

AU - Lawrence, William

AU - Plante, Jessica

AU - Ramsauer, Katrin

AU - Schrauf, Sabrina

AU - Weaver, Scott

PY - 2019/7/31

Y1 - 2019/7/31

N2 - BACKGROUND: Chikungunya virus (CHIKV) infection can result in chikungunya fever (CHIKF), a self-limited acute febrile illness that can progress to chronic arthralgic sequelae in a large percentage of patients. A new measles virus-vectored vaccine was developed to prevent CHIKF, and we tested it for immunogenicity and efficacy in a nonhuman primate model. METHODS: Nine cynomolgus macaques were immunized and boosted with the measles virus-vectored chikungunya vaccine or sham-vaccinated. Sera were taken at multiple times during the vaccination phase to assess antibody responses against CHIKV. Macaques were challenged with a dose of CHIKV previously shown to cause fever and viremia, and core body temperature, viremia, and blood cell and chemistry panels were monitored. RESULTS: The vaccine was well tolerated in all macaques, and all seroconverted (high neutralizing antibody [PRNT80 titers, 40-640] and enzyme-linked immunosorbent assay titers) after the boost. Furthermore, the vaccinated primates were protected against viremia, fever, elevated white blood cell counts, and CHIKF-associated cytokine changes after challenge with the virulent La Reunión CHIKV strain. CONCLUSIONS: These results further document the immunogenicity and efficacy of a measles-vectored chikungunya vaccine that shows promise in Phase I-II clinical trials. These findings are critical to human health because no vaccine to combat CHIKF is yet licensed.

AB - BACKGROUND: Chikungunya virus (CHIKV) infection can result in chikungunya fever (CHIKF), a self-limited acute febrile illness that can progress to chronic arthralgic sequelae in a large percentage of patients. A new measles virus-vectored vaccine was developed to prevent CHIKF, and we tested it for immunogenicity and efficacy in a nonhuman primate model. METHODS: Nine cynomolgus macaques were immunized and boosted with the measles virus-vectored chikungunya vaccine or sham-vaccinated. Sera were taken at multiple times during the vaccination phase to assess antibody responses against CHIKV. Macaques were challenged with a dose of CHIKV previously shown to cause fever and viremia, and core body temperature, viremia, and blood cell and chemistry panels were monitored. RESULTS: The vaccine was well tolerated in all macaques, and all seroconverted (high neutralizing antibody [PRNT80 titers, 40-640] and enzyme-linked immunosorbent assay titers) after the boost. Furthermore, the vaccinated primates were protected against viremia, fever, elevated white blood cell counts, and CHIKF-associated cytokine changes after challenge with the virulent La Reunión CHIKV strain. CONCLUSIONS: These results further document the immunogenicity and efficacy of a measles-vectored chikungunya vaccine that shows promise in Phase I-II clinical trials. These findings are critical to human health because no vaccine to combat CHIKF is yet licensed.

KW - chikungunya virus

KW - measles virus

KW - nonhuman primate

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85068817206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068817206&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiz202

DO - 10.1093/infdis/jiz202

M3 - Article

VL - 220

SP - 735

EP - 742

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -